Ruxience: Clinical Trials

51 trials of Ruxience, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

26 recruiting, 11 active not recruiting, 7 completed, 2 suspended. 51 Phase 2, 12 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 251Recruiting 26, Active not recruiting 11, Completed 7, Suspended 2, Terminated 2, Not yet recruiting 1, Unknown 1, Withdrawn 1
Phase 112Recruiting 5, Active not recruiting 3, Completed 2, Terminated 1, Unknown 1
Phase 33Active not recruiting 2, Recruiting 1

Follow Ruxience: new trials by email Literature Review of Ruxience trials Research Report on Ruxience

Trials (filtered) newest first · largest first

All 51 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Phase 2 / Phase 3RecruitingNational Cancer Institute (NCI)2712027-07-272026-11-17
Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Phase 1 / Phase 2RecruitingCity of Hope Medical Center582026-12-212026-10-22
Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)
Loncastuximab tesirine, Rituximab or rituximab biosimilar - Post-transplant Lymphoproliferative Disorder
Phase 1 / Phase 2RecruitingUniversity of Utah232026-11-052026-11-09
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Phase 2RecruitingCity of Hope Medical Center352026-10-232026-10-29
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma
Phase 2RecruitingUniversity of Washington302026-10-092026-10-15
Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma
Phase 2RecruitingAIDS Malignancy Consortium432026-09-162026-11-17
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection - Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
Phase 2RecruitingCity of Hope Medical Center432026-07-272026-08-28
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)842026-05-292026-07-31
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
Phase 2SuspendedUniversity of Washington302026-05-082026-09-29
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
Acalabrutinib, Rituximab, Glofitamab - Phase 2 Study, MCL
Phase 2RecruitingM.D. Anderson Cancer Center302026-04-012026-11-17
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1
Phase 2RecruitingUniversity of Washington332026-03-302026-08-13
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Venetoclax, Rituximab - Lymphoma, Marginal Zone Lymphoma
Phase 2RecruitingGottfried von Keudell, MD PhD332026-02-112026-03-13
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma
Phase 2RecruitingUniversity of Washington182025-12-072026-10-21
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma
Phase 2RecruitingCity of Hope Medical Center532025-10-102026-10-13
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Phase 2RecruitingUniversity of California, Davis252025-07-312026-06-30
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Phase 2RecruitingFred Hutchinson Cancer Center302025-06-022026-10-30
MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
Bendamustine, Rituximab - Lymphoma, Indolent Non-hodgkin Lymphoma
Phase 2Not yet recruitingFox Chase Cancer Center242025-06-012025-01-06
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Bendamustine, Rituximab, Cytarabine - Mantle Cell Lymphoma, Lymphoma
Phase 2RecruitingChristine Ryan602025-04-222026-02-20
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
Phase 2RecruitingMayo Clinic412025-04-022026-10-20
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Roginolisib, Venetoclax, Rituximab - Leukemia, Relapsed Leukemia
Phase 1 / Phase 2RecruitingJennifer R. Brown, MD, PhD642025-03-192026-02-11

Showing 20 of 51. Sign in to see all of them.

Conditions studied

Lymphoma, Large B-Cell, Diffuse (9)  ·  Burkitt Lymphoma (8)  ·  Lymphoma (7)  ·  Lymphoma, B-Cell, Marginal Zone (7)  ·  Lymphoma, Mantle-Cell (7)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (5)  ·  Lymphoma, B-Cell (4)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (4)  ·  Lymphoma, Follicular (3)  ·  Hodgkin Disease (2)  ·  Leukemia (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Anemia, Sickle Cell (1)  ·  Diabetes Mellitus, Type 1 (1)  ·  Disease (1)

Sponsors

National Cancer Institute (NCI) (12)  ·  M.D. Anderson Cancer Center (6)  ·  University of Washington (6)  ·  City of Hope Medical Center (5)  ·  Academic and Community Cancer Research United (3)  ·  Mayo Clinic (2)  ·  University of California, Davis (2)  ·  AIDS Malignancy Consortium (1)  ·  BioInvent International AB (1)  ·  Children's Oncology Group (1)  ·  Christine Ryan (1)  ·  Columbia University (1)  ·  Fox Chase Cancer Center (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Gottfried von Keudell, MD PhD (1)

Countries

United States (50)  ·  Canada (2)  ·  Australia (1)  ·  Brazil (1)  ·  Germany (1)  ·  Poland (1)  ·  Spain (1)  ·  Sweden (1)

Top investigators

Geoffrey Shouse (2)  ·  Grzegorz S Nowakowski (2)  ·  Joseph M Tuscano (2)  ·  Mengyang Di, MD, PhD (2)  ·  Alain Mina, M.D. (1)  ·  Alexey V Danilov (1)  ·  Ariela Noy (1)  ·  Birte Wistinghausen (1)  ·  Bouthaina S Dabaja (1)  ·  Catherine S Diefenbach (1)  ·  Christine Ryan, MD (1)  ·  Claire Tiger, MD, PhD (1)  ·  Daniel Moore, MD (1)  ·  Daniel O Persky (1)  ·  Elias Jabbour, MD (1)

Results publications

PMID 28945884, PMID 29531316, PMID 29785709, PMID 30530801, PMID 30575311, PMID 34555839, PMID 34634256, PMID 34686472, PMID 34797699, PMID 35074072, PMID 35787017, PMID 36521030, PMID 38163318, PMID 39352751, PMID 39735417, PMID 40331908, PMID 40550489, PMID 40802906, PMID 42305039, PMID 42660130

NIH funding

P30CA033572 (5), U10CA180821 (4), P30CA015083 (3), U10CA180888 (3), P30CA093373 (2), U10CA031946 (2), P30CA060553 (1), P50CA097274 (1), U10CA021115 (1), U10CA032102 (1), U10CA180820 (1), U10CA180886 (1), U24CA196172 (1), UC4DK117009 (1), UM1CA121947 (1)